Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Diagnostic
- Cancer
- Therapeutic
- Biotechnology
- Disease
- cell therapy
- Proteins
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 229530
License Grant
The Licensor of United Kingdom and Licensee into an exclusive license agreement granting an exclusive license, with the right to sublicense, under certain patents and technology relating to the de-immunization of Licensees cytotoxin Bouganin. Licensee has the worldwide exclusive right, with the right to sublicense, under the licensed patents and technology to, among other things, make, have made, use or sell products incorporating deBouganin.
License Property
The de-immunized cytotoxin is known as deBouganin, and has been incorporated into Licensees product candidate, VB6-845d, relating to the treatment of cancer.
Field of Use
This agreement is for therapeutic and in vivo diagnostic purposes in humans. Licensee is a biologics oncology company focused primarily on designing, engineering and developing targeted protein therapeutics, or TPTs, a single protein therapeutics composed of targeting moieties genetically fused via a peptide linker domain to cytotoxic protein payloads that are produced through proprietary recombinant one-step manufacturing process, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells.
IPSCIO Record ID: 363531
License Grant
Licensor granted the Turkish Licensee an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus.
License Property
Vicineum is a locally administered fusion protein developed for bladder cancer. Vicineum is comprised of a recombinant fusion protein that targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A. Vicineum is constructed with a stable, genetically engineered peptide tether to ensure the payload remains attached until it is internalized by cancer cell, which is believed to decrease the risk of toxicity to healthy tissues, thereby improving its safety.
Field of Use
Field of use is for the treatment of BCG-unresponsive NMIBC, a non-muscle invasive bladder cancer.
IPSCIO Record ID: 237233
License Grant
Licensor grants a non-exclusive, worldwide license, without the right to grant sublicenses, to Licensor Patent Rights, Technology and Improvements for LIcensee to perform research and development solely on Licensees behalf in the Field of Use during the Technology Term.
Licensor grants a non-exclusive, worldwide license to Licensor Patent Rights, Technology and Improvements to research, develop, make, have made, use, import, offer to sell and sell collaboration products and non-collaboration products in the Field of Use and to sublicense solely the research, development, manufacture, use, importation and sale of such collaboration products and non-collaboration products in the Field of Use.
Licensor grants an exclusive, worldwide license to research, develop, make, have made, use, import, offer to sell and sell collaboration products in the Field of Use and to sublicense the research, development, manufacture, use, importation and sale of such collaboration products in the Field of Use.
Licensor grants a non-exclusive, worldwide license to Licensor Patent Rights to research, develop, make, have made, use, import, offer to sell and sell non-Licensor products in the Field of Use and to sublicense solely the research, development, manufacture, use, importation and sale of such non-Licensor products in the Field of Use.
License Property
Collaboration Product shall mean any product incorporating or derived from any peptide or antibody compound, and the sequence contained therein, discovered by Licensor using the Licensor Technology during the collaboration term, and that binds to an Licensee Target.
The patents relate to Gene encoding and novel protein binding, but specifically exclude Claim 66 in U.S. Patent No. 5,223,409 to the extent that it covers DNA molecules encoding single chain antibodies, or (ii) any claim to specific protein or peptide sequences, or nucleic acids encoding the same, that bind to a specific biological or molecular target.
Field of Use
The Field of Use shall mean the Therapeutic Field, Diagnostic Field and/or Research Reagent Field, and shall not include any in vivo diagnostic uses other than as provided herein, or any purification or separations, agricultural, industrial enzymes or any other uses.
Research Reagent Field shall mean the use of one or more peptides, antibodies, or antibody-antigen or peptide-target combinations (whether in a microarray format or other format) for research purposes.
Therapeutic Field shall mean all human therapeutic and prophylactic uses, and any in vivo diagnostic uses for a Licensee Target which is necessary for HGS successful commercialization of a human therapeutic or prophylactic Collaboration Product, non-collaboration product or non-Licensor product.
Diagnostic Field shall mean all in vitro research, analysis, detection or diagnostic uses, and not for any in vivo diagnostic, therapeutic, purification_ or separations, agricultural, industrial enzyme or other uses.
Licensor Field shall mean all agricultural, industrial enzyme, and purification and separation uses.
IPSCIO Record ID: 531
License Grant
Licensor hereby grants undisclosed Licensee and its Affiliates a world-wide, nonexclusive, royalty-bearing license (without the right to grant sublicenses) under Patent Rights (i) to research and develop, make, have made, use, sell and have sold Licensed Products in the Field of Use and (ii) to research and develop, make and use Licensed Intermediates in the Field of Use for sale or transfer to any Third Party Transferee.
License Property
Licensor has the right to grant licenses to and under certain technology described and claimed in U.S. Patent No. 5,223,409 entitled Directed Evolution of Novel Binding Proteins, U.S. Patent No. 5,403,484 entitled Viruses Expressing Chimeric Binding Proteins, and U.S. Patent No. 5,571,698 entitled Directed Evolution of Novel Binding Proteins, U.S. Patent No. 5,837,500 entitled Directed Evolution of Novel Binding Proteins, and associated patent rights.
'LICENSED INTERMEDIATE' shall mean any fusion protein (including without limitation any chimeric binding protein), genetic package (including without limitation any virus, spore or cell) or other intermediate compound, or any compound derived from any of the foregoing, that is (i) discovered, made or developed by Licensee using a method covered by Patent Rights or (ii) is otherwise covered by Patent Rights.
Licensed Product shall mean any product intended for sale to an End User as an In Vitro diagnostic or research reagent, and sold in the form of an immunoassay kit or vial containing one or more antibodies as a binding moiety that is discovered, made or developed, whether by Licensee, its Affiliates or any Third Party Transferee, using a Licensed Intermediate or a method covered by Patent Rights.
Field of Use
Field of Use shall mean human In Vitro diagnostic or research reagent uses, and not for any therapeutic, In Vivo diagnostic, purification or separations, agricultural, industrial enzymes or other purposes.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
